The Chinese Early-onset Hypertension Study (CHESS)

Hypertension Clinical Trial

— CHESS  

Official title:

The Chinese Early-onset Hypertension Study (CHESS)

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02819674
• Other study ID #: CEHS-2016
• Status: Recruiting
• Phase: N/A
• First received: May 20, 2016
• Last updated: January 7, 2018
• Start date: October 2012
• Est. completion date: December 2020

Study information

• Verified date: January 2018
• Source: China National Center for Cardiovascular Diseases
• Contact: Lei Song, MD.& PhD.
• Phone: 86-13810532620
• Email: clinicalfw[@]163.com
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Hypertension (HTN) is the most important cardiovascular risk factor which is responsible for 50% of cardiovascular morbidity and mortality, and also a substantial public health problem affecting approximately 1/4 of the adult population in industrialized societies and over 1 billion people worldwide. Chronically elevated blood pressure without well control puts people at increased risk of target organ damages, including stroke, myocardial infarction, congestive heart failure, end-stage renal disease, blindness, and death. Especially, these damages are dramatically more severe in the early-onset hypertensive population.

Description:

In this study, the hypertensive individuals are consecutively recruited from multiple centers, with an early onset age (less than 40 when diagnosed). A complete clinical history (information on history of hypertension, demographic characteristics, personal and family medical history) are collected by a trained staff using a standardized questionnaire on the first day of baseline observation, and physical examination are also collected in a standard procedure. Blood samples are collected after 12-hour overnight fast and biological variables are determined. Genomic DNA is isolated from leukocytes according to a standard procedure. The individuals will receive follow-up in an ordinal system. The investigators will focus on the clinical and genetic features, genotype-phenotype correlations and influencing factors of prognosis in Chinese early-onset hypertension patients.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 5000
• Est. completion date: December 2020
• Est. primary completion date: December 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• In accordance with the diagnosis of hypertension (BP=140/90mmHg), and less than 40 years when diagnosed

Exclusion Criteria:

Related Conditions & MeSH terms

• Hypertension

Locations

Country	Name	City	State
China	Fuwai hospital	Beijing	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
China National Center for Cardiovascular Diseases

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	primary mortality of early-onset hypertension	the primary mortality of early-onset hypertension	through study completion, an average of 5 years
Secondary	secondary outcomes of heart	The incidence rate of left ventricular hypertrophy, myocardial infarction, congestive heart failure, and arrhythmia.	through study completion, an average of 5 years
Secondary	secondary outcomes of brain	The incidence rate of stroke (include cerebral hemorrhage and cerebral ischemia)	through study completion, an average of 5 years
Secondary	secondary outcomes of kidney	The incidence rate of hypertensive renal injure and end-stage renal disease	through study completion, an average of 5 years
Secondary	secondary outcomes of eyes	The incidence rate of hypertensive eye injure	through study completion, an average of 5 years